Research Topics
Species | Joseph H FriedmanSummaryAffiliation: Brown University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instrumentsKelvin L Chou
Department of Clinical Neurosciences, Brown Medical School, Providence, Rhode Island, USA
Clin Neuropharmacol 28:215-9. 2005....
Doctor's revengeJoseph H Friedman
Med Health R I 89:296. 2006
Self perceived weakness in Parkinson's diseaseJoseph H Friedman
Movement Disorders Program, Butler Hospital, Dept of Neurology, Alpert Medical School of Brown University, 345 Blackstone Blvd, Providence, RI 02906, USA
Parkinsonism Relat Disord 18:887-9. 2012..Relative weakness, and early muscle fatigue may be demonstrated on testing but frank weakness should not be apparent on routine clinical examination...
Atypical antipsychotic drugs in the treatment of Parkinson's diseaseJoseph H Friedman
Department of Neurology, Movement Disorders Program, Butler Hospital, Alpert Medical School of Brown University, Providence, RI 02906, USA
J Pharm Pract 24:534-40. 2011..The other atypical have been the subjects of conflicting open label reports. The effects of the atypicals in PD psychosis is reviewed...
Gait in the elderlyJoseph H Friedman
NeuroHealth, Warwick, RI 02886, USA
Med Health R I 91:134-5. 2008
Sleep disturbances and Parkinson's diseaseJoseph H Friedman
Neuro Health Parkinson s Disease and Movement Disorders, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA
CNS Spectr 13:12-7. 2008..Treatment plans for patients with Parkinson's disease who experience sleep disorders aim to improve nighttime sleep or daytime wakefulness, and treatment options vary by sleep disorder...
Rhinorrhea and olfaction in Parkinson diseaseJoseph H Friedman
Neuro Health, 227 Centerville Rd, Warwick, RI 02886, USA
Neurology 70:487-9. 2008
Rhinorrhea is increased in Parkinson's diseaseJoseph H Friedman
Parkinson s Disease and Movement Disorders Center of NeuroHealth, Warwick, Rhode Island 02886, USA
Mov Disord 23:452-4. 2008..These observations confirm that rhinorrhea is a common problem and raise the questions as to whether some olfactory impairment found in PD could be confounded by rhinorrhea and also whether rhinorrhea may be a premotor symptom...
Fatigue in Parkinson's disease: a reviewJoseph H Friedman
NeuroHealth, Warwick, Rhode Island 02886, USA
Mov Disord 22:297-308. 2007..This article reviews what is known about the symptom, putting it into the context of fatigue in other disorders, and outlines a program for developing better understanding and therapy...
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's diseaseJoseph H Friedman
Parkinson Disease and Movement Disorders Center, NeuroHealth, Warwick, Rhode Island 02886, USA
Mov Disord 21:2078-81. 2006..While some patients had a favorable response, aripiprazole was associated with an exacerbation of motor symptoms. In this small study on psychosis in PD, aripiprazole did not appear promising...
Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warningJoseph H Friedman
NeuroHealth Parkinson s Disease and Movement Disorders Center, 227 Centerville Rd, Warwick, RI 02886, USA
Neurology 67:564-6. 2006..In this article, the author reviews the history of these developments and raises issues that still need to be addressed by the neurologic community...
Fatigue in Parkinson's disease patientsJoseph H Friedman
Joseph H Friedman, MD Parkinson s Disease and Movement Disorders Center, NeuroHealth, 227 Centerville Road, Warwick, RI 02886, USA
Curr Treat Options Neurol 11:186-90. 2009..Some patients may take their doses unevenly, with more or less for the morning dose. Patients who tend to go to bed late at night may take their doses three times daily...
Neuropsychiatric disorders: What do neurologists think about conversion disorder?Joseph H Friedman
Program in Movement Disorders, Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906, USA
Nat Rev Neurol 7:306-7. 2011..Instead, the results indicate that the neurologist’s diagnosis is influenced largely by their communication with the patients...
Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behavioursJoseph H Friedman
Department of Neurology, Alpert School of Medicine, Brown University, Providence, Rhode Island 02906, USA
Int J Neurosci 121:472-6. 2011..This report is a compilation of vignettes describing these behavioral problems that the treating neurologist or psychiatrist attributed to the medications used for treating PD...
Fatigue in Parkinson's diseaseJoseph H Friedman
Movement Disorders Program, Butler Hospital, 345 Blackstone Blvd, Providence, RI 02906, USA
Expert Opin Pharmacother 12:1999-2007. 2011..EXPERT OPINION: Fatigue is a common and severe problem in Parkinson's disease. Virtually nothing is known about it aside from its epidemiology. It is an area greatly in need of investigation...
Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's diseaseJoseph H Friedman
NeuroHealth, Parkinson s Disease and Movement Disorders Center, Warwick, Rhode Island 02886, USA
Mov Disord 25:805-22. 2010..The committee concluded that current scales are adequate for fatigue studies in PD but that studies on sensitivity and specificity of the scales are still needed...
Parkinson's disease psychosis 2010: a review articleJoseph H Friedman
Dept of Neurology, Alpert Medical School of Brown University, Butler Hospital, 345 Blackstone Blvd, Providence, RI 02906, USA
Parkinsonism Relat Disord 16:553-60. 2010..Only clozapine has level I evidence to support its use. Quetiapine is the only other anti-psychotic free of motor side effects, but it has failed double blind placebo controlled trials to demonstrate efficacy...
Managing idiopathic Parkinson's disease in patients with schizophrenic disordersJoseph H Friedman
Movement Disorders Program, Butler Hospital, 345 Blackstone Blvd, Providence, RI 02903, USA
Parkinsonism Relat Disord 17:198-200. 2011..None of the patients suffered worsened psychosis from l-Dopa or a dopamine agonist if taking antipsychotics, and motor response did not appear blunted...
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD StudyElise Caccappolo
Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
J Int Neuropsychol Soc 17:91-100. 2011..Carriers of parkin mutations, whether or not they have PD, do not perform differently on neuropsychological measures as compared to noncarriers. The cognitive functioning of parkin carriers over time warrants further study...
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease studyRoy N Alcalay
Department of Neurology, Columbia University, New York, NY 10032, USA
Arch Neurol 67:1116-22. 2010..To assess the frequency and clinical characteristics of carriers of previously identified mutations in 6 genes associated with early-onset Parkinson disease (PD) and provide empirical data that can be used to inform genetic counseling...
Scales to assess psychosis in Parkinson's disease: Critique and recommendationsHubert H Fernandez
Department of Neurology, McKnight Brain Institute University of Florida, Gainesville, Florida 32611, USA
Mov Disord 23:484-500. 2008..The CGIS is suggested as a secondary outcome scale to measure change and response to treatment over time...
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's diseaseRoy N Alcalay
Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
J Clin Exp Neuropsychol 32:775-9. 2010..GBA carriers reported more impairment, but MMSE performance did not differ among genetic groups. Detailed neuropsychological testing is required to explore the association between cognitive impairment and GBA mutations...
Long-term outcome of quetiapine use for psychosis among Parkinsonian patientsHubert H Fernandez
Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
Mov Disord 18:510-4. 2003..6; 95% CI = 1.4-92.9). Also, patients who developed motor worsening while on quetiapine tended to be more demented (P = 0.07)...
Atypical antipsychotics in Parkinson-sensitive populationsJoseph H Friedman
Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
J Geriatr Psychiatry Neurol 15:156-70. 2002..Suggestions are made for future research to improve the interpretability of these studies...
The management of psychosis in movement disorder patientsKelvin L Chou
Department of Clinical Neurosciences, Warren Alpert Medical School of Brown University, Providence, RI, USA
Expert Opin Pharmacother 8:935-43. 2007..This review covers the management of psychosis in three different movement disorders: Parkinson's disease, dementia with Lewy bodies and Huntington's disease...
Falls and the falls efficacy scale in Parkinson's diseaseAlissa A Thomas
Department of Neurology, Dartmouth Hitchcock Medical Center, Warren Alpert Medical School of Brown University, Hanover, NH, USA
J Neurol 257:1124-8. 2010..The lack of fear of falling but frequent falls in this small subgroup may suggest that special techniques to instill suitable caution to prevent falls are necessary, or may make training of these patients impossible...
Phenomenology of dreams in Parkinson's diseaseLeora L Borek
NeuroHealth Parkinson s Disease and Movement Disorders Center, Warwick, Rhode Island, USA
Mov Disord 22:198-202. 2007..Men with PD had more aggressive dreams compared to females with PD. Aggressive dream content was characteristic of RBD patients and sex differences exist in the dream content of the PD population...
Testosterone not associated with violent dreams or REM sleep behavior disorder in men with Parkinson'sKelvin L Chou
NeuroHealth Parkinson s Disease and Movement Disorders Center, Warwick, Rhode Island 02886, USA
Mov Disord 22:411-4. 2007..While dream content appears to be more aggressive in PD patients with clinical RBD, the presence of violent dreams or clinical RBD is not associated with testosterone levels in men with PD...
Management of the behavioral aspects of Parkinson's diseaseLeora L Borek
Neurohealth Alzheimer s Disease and Movement Disorders Center, and Department of Geriatric Psychiatry, Butler Hospital, Warren Alpert Medical School of Brown University, RI, USA
Expert Rev Neurother 7:711-25. 2007..This review focuses on the management of the most common behavioral symptoms of Parkinson's disease, including depression, anxiety, psychosis, dementia, delirium, sleep disorders, fatigue, apathy, emotionalism and compulsive behaviors...
Non-motor aspects of Parkinson's diseaseLeora L Borek
Department of Geriatric Psychiatry, Brown University School of Medicine, Providence, RI, USA
CNS Spectr 11:541-54. 2006..The phenomenology, pathology, and treatment of the behavioral symptoms of Parkinson's disease will be discussed...
Physical activity and neuropsychiatric symptoms of Parkinson diseaseAna M Abrantes
Butler Hospital, Providence, RI 02906, USA
J Geriatr Psychiatry Neurol 25:138-45. 2012..Developing and tailoring exercise programs that incorporate specific preferences may result in more effective interventions for patients with PD...
A comparison of fatigue measures in Parkinson's diseaseJanet Grace
Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI, USA
Parkinsonism Relat Disord 13:443-5. 2007..PD patients and healthy controls differed significantly on both measures. PD patients endorsed significantly more fatigue. The PFS is a reliable, valid fatigue measure...
Diabetes mellitus among parkinsonian patients treated chronically with clozapineHubert H Fernandez
Department of Neurology, University of Florida, Gainesville, FL, USA
Parkinsonism Relat Disord 10:439-41. 2004..3% for ages > or = 60 years). In this small study, parkinsonian patients on long-term, low dose clozapine were not at increased risk for developing DM. Larger controlled prospective studies are needed to confirm this...
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work groupBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14620, USA
Mov Disord 22:1061-8. 2007..These criteria require validation and may be refined, but form a starting point for studies of the epidemiology and pathophysiology of PDPsy, and are a potential indication for therapy development...
Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodiesHubert H Fernandez
Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
J Clin Psychiatry 63:513-5. 2002..Most clinicians perceive psychosis in dementia with Lewy bodies (DLB) as more difficult to treat than Parkinson's disease, yet there are no reports comparing the antipsychotic response between the 2 disorders...
Olfaction and apathy in Parkinson's diseaseChristina K Cramer
The Alpert Medical School at Brown University, 343 Lloyd ave, Providence, RI 02906, USA
Parkinsonism Relat Disord 16:124-6. 2010..However, no study until this point has been published investigating whether there is any association between olfactory dysfunction and apathy in PD patients...
Treatment of psychosis in Parkinson's disease: safety considerationsHubert H Fernandez
Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
Drug Saf 26:643-59. 2003..Electroconvulsive treatment is generally reserved for the patient with psychotic depression who is unable to tolerate any pharmacological therapy...
Long-term outcome of clozapine use for psychosis in parkinsonian patientsHubert H Fernandez
Department of Clinical Neurosciences, Brown Uniersity School of Medicine, Providence, Rhode Island, USA
Mov Disord 19:831-3. 2004..Our data are more consistent with recently published long-term outcome data suggesting an improvement in the prognosis of parkinsonian patients with psychosis with the use of atypical antipsychotic agents such as clozapine...
Hemiballismus from a parietal stroke in a Parkinson patientMotasem Al-Yacoub
Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
Mov Disord 19:986-8. 2004..This suggests that HB itself, whether from a lesion in the subthalamic nucleus or elsewhere, is not what improves motor function in PD; instead, the physiological function of the damaged structure is the determining factor...
Botulinum toxin type B for gait freezing in Parkinson's diseaseHubert H Fernandez
Department of Clinical Neuroscience, Brown University School of Medicine, Providence, RI, USA
Med Sci Monit 10:CR282-4. 2004..Freezing of Gait (FOG) can be a serious problem in Parkinson's disease (PD) and is usually refractory to medical treatment. Botulinum toxin (BTX) type A has been reported to relieve FOG in small open label studies...
Levodopa addiction in idiopathic Parkinson diseaseLeora L Borek
Department of Neurology, Memorial Hospital, Brown University, Providence, RI, USA
Neurology 65:1508. 2005
Are atypical antipsychotics associated with a reduced risk of developing parkinsonism?Kelvin L Chou
Department of Clinical Neurosciences, Brown University, Providence, RI, USA
Nat Clin Pract Neurol 2:132-3. 2006
Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's diseaseDeborah A Cahn-Weiner
Memorial Hospital of Rhode Island and Brown Medical School, Pawtucket 02860, USA
Neuropsychiatry Neuropsychol Behav Neurol 15:79-87. 2002..To compare the cognitive and behavioral profiles of Alzheimer's disease (AD) and cognitively impaired patients with Parkinson's disease (PD) and to determine the individual measures that best discriminate the two patient groups...
Presumed rapid eye movement behavior disorder in Machado-Joseph disease (spinocerebellar ataxia type 3)Joseph H Friedman
Department of Clinical Neurosciences, Brown University Medical School, Providence, Rhode Island 02860, USA
Mov Disord 17:1350-3. 2002..Polysomnography was normal in 1 patient. Two of these patients had had single photon emission computed tomographic imaging of the dopamine transporter 1 year previously...
Reduction of freezing of gait in Parkinson's disease by repetitive robot-assisted treadmill training: a pilot studyAlbert C Lo
VA RR and D Center of Excellence Center for Restorative and Regenerative Medicine, Providence VA Medical Center, 830 Chalkstone Ave, Providence, RI 02908, USA
J Neuroeng Rehabil 7:51. 2010..The purpose of this study was to examine the potential effect of continuous physical cueing using robot-assisted sensorimotor gait training on reducing FOG episodes and improving gait...
Current use of clozapine in Parkinson disease and related disordersAlissa A Thomas
Alpert Medical School, Brown University, Providence, RI 02886, USA
Clin Neuropharmacol 33:14-6. 2010..Clozapine has been shown to be effective in the treatment of Parkinson disease psychosis and tremor; however, use of clozapine has been limited because of potential adverse effects and stringent monitoring criteria...
Classification and treatment of tardive syndromesHubert H Fernandez
Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island, USA
Neurologist 9:16-27. 2003..Tardive syndromes are a group of delayed-onset abnormal involuntary movement disorders induced by a dopamine receptor blocking agent. There are several phenomenologically distinct types of TS...
REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3)Joseph H Friedman
Department of Clinical Neurosciences, Brown University School of Medicine, Providence, Rhode Island 02860, USA
Mov Disord 18:1520-2. 2003..Our results support the previous observation that RBD-like behaviors are significantly increased in SCA-3...
Monozygotic twins discordant for Huntington disease after 7 yearsJoseph H Friedman
Department of Clinical Neurosciences, Brown University School of Medicine, Providence, RI, USA
Arch Neurol 62:995-7. 2005..We have identified increased cigarette use and longer exposure to various industrial toxins as potential explanations for the earlier onset in one twin...
Tardive syndromes in the elderlyKelvin L Chou
Department of Clinical Neurosciences, Brown Medical School, 227 Centerville Road, Warwick, RI 02886, USA
Clin Geriatr Med 22:915-33, viii. 2006..This article summarizes the clinical phenomenology, pathophysiology, epidemiology, and treatment of these disorders in elderly individuals...
Dextromethorphan-induced neurologic illness in a patient with negative toxicology findingsJoseph K Cherkes
Department of Toxicology, Rhode Island Hospital, Providence, USA
Neurology 66:1952-3. 2006
Hospitalization in Parkinson disease: a survey of National Parkinson Foundation CentersKelvin L Chou
Department of Neurology, University of Michigan, Ann Arbor, MI 48109 5316, USA
Parkinsonism Relat Disord 17:440-5. 2011..To explore current practices and opinions regarding hospital management of Parkinson disease (PD) patients in specialized PD Centers...
Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three casesMarjorie A Murphy
Department of Ophthalmology, Rhode Island Hospital, Brown Medical School MAM, RI 02903, USA
J Clin Neurosci 12:941-5. 2005..We describe three cases diagnosed during life as PSP but found to have another neurologic disorder at autopsy. No explanation for the gaze palsies was found in any case...
Executive and emotional dysfunction in Machado-Joseph diseaseTricia M Zawacki
Department of Psychiatry and Human Behavior, Brown University School of Medicine, Providence, Rhode Island 02903, USA
Mov Disord 17:1004-10. 2002..Impaired executive abilities and emotional functioning in MJD patients is consistent with disruption of frontal-subcortical systems...
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson diseaseRoy N Alcalay
Department of Neurology, Columbia University, New York, NY 10032, USA
Arch Neurol 66:1517-22. 2009....
Anticholinergics in dementia and other confounding problemsJoseph H Friedman
Am J Geriatr Psychiatry 14:384; author reply 384-5. 2006
Iatrogenesis imperfectaJoseph H Friedman
Med Health R I 85:198. 2002
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's diseaseAlan Breier
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
Biol Psychiatry 52:438-45. 2002..Future studies involving gradual dose titration are needed to explore further olanzapine's optimum use for patients with PD with treatment-related psychosis...
Risperidone and Parkinson's diseaseStewart A Factor
Mov Disord 17:221-2. 2002
Effects of fatigue on physical activity and function in patients with Parkinson's diseaseCarol Ewing Garber
Bouve College of Health Sciences, Department of Cardiopulmonary and Exercise Sciences, Northeastern University, Boston, MA 02115, USA
Neurology 60:1119-24. 2003..To characterize the relationships between symptoms of fatigue, physical activity, physical function, and functional capacity in patients with idiopathic PD...
Re: Klintenberg et al, tardive dyskinesia model in the common marmosetJoseph H Friedman
Mov Disord 18:114-5. 2003
Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experienceHubert H Fernandez
Department of Neurology, University of Florida College of Medicine, Gainesville, FL 32610
Clin Neuropharmacol 27:4-5. 2004..Our preliminary experience with aripiprazole is mixed but not very encouraging. Controlled studies are needed to evaluate aripiprazole in parkinsonian patients...
Dreams in neurological diseasesJoseph H Friedman
Med Health R I 89:388. 2006
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trialConnie Marras
Division of Neurology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
Mov Disord 23:653-9; quiz 776. 2008..Our focus in clinical care needs to be broadened beyond assessing and treating Parkinsonism, recognizing the impact of mood, cognition and function on HRQOL...
"... But I can still sue you, can't I"?Joseph H Friedman
Med Health R I 90:170. 2007
Mood and sleep in Parkinson's diseaseLeora L Borek
Department of Psychiatry and Human Behavior, Butler Hospital
J Clin Psychiatry 67:958-63. 2006..To determine whether severity of depression and severity of anxiety were associated with particular types of sleep disturbance in patients with Parkinson's disease...
Ophthalmologic features of Parkinson's diseaseJoseph H Friedman
Neurology 63:940-1; author reply 940-1. 2004
Historical perspective on movement disordersJoseph H Friedman
Brown University Medical School and the Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, RI 02860, USA
J Clin Psychiatry 65:3-8. 2004..With the development of the atypical antipsychotics, the incidence and prevalence of tardive dyskinesia have dropped remarkably, suggesting that psychosis, its treatment, and dyskinesias are not inextricably linked...
Parkinsonism in a nursing home: underrecognitionJoseph H Friedman
Division of Neurology, Memorial Hospital of Rhode Island, 111 Brewster St, Pawtucket, RI 02860, USA
J Geriatr Psychiatry Neurol 17:39-41. 2004..02). Only 1 patient with drug-induced parkinsonism and 3 residents with previously diagnosed Parkinson's disease had chart notes indicating that parkinsonism had been recognized...
Needless testsJoseph H Friedman
Med Health R I 85:262-3. 2002
Genetic markers and the majority's right not to knowJacob Appel
Mov Disord 19:113-4. 2004
More on repetitive behaviors in Parkinson's diseaseJoseph H Friedman
Mov Disord 20:509; author reply 509-10. 2005
Atypical antipsychotics have very different adverse effect profiles and should not be lumped togetherJoseph H Friedman
Arch Intern Med 166:586; author reply 586-7. 2006
Randomized, double-blind, placebo-controlled trials: the gold standard?Joseph H Friedman
Med Health R I 87:262-3. 2004
Sleep and fatigue in Parkinson's diseaseJoseph H Friedman
Division of Neurology, Memorial Hospital of Rhode Island, Pawtucket, RI 02860, USA
Parkinsonism Relat Disord 10:S27-35. 2004..An overview of sleep disorders in PD and an approach to therapy will also be outlined. The little that is known about fatigue in PD will be reviewed...
Re: Atypical antipsychotics mechanisms of actionJoseph H Friedman
Can J Psychiatry 48:62; author reply 62-4. 2003
Introduction to geriatric neurology issueJoseph H Friedman
Med Health R I 91:126. 2008
Rating instrumentsJoseph H Friedman
Med Health R I 91:2-3. 2008
Neuroprotective trials: no longer a cautious optimismJoseph H Friedman
Med Health R I 91:158. 2008
GratificationJoseph H Friedman
Med Health R I 86:374. 2003
Folie a deuxJoseph H Friedman
Med Health R I 87:2-3. 2004
Chronic pain in Machado-Joseph disease: a frequent and disabling symptomMarcondes C Franca
Department of Neurology, Universidade Estadual de Campinas UNICAMP, Rua Tessália Vieira de Camargo, 126 Cidade Universitaria Zeferino Vaz, Campinas, SP, Brazil
Arch Neurol 64:1767-70. 2007..Although patients frequently report pain, systematic evaluation of this clinical feature is lacking...
A good result isn't always a good resultJoseph H Friedman
Med Health R I 90:202. 2007
Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control studyRosa Liperoti
Center for Medicine of Aging, Department of Gerontology and Geriatrics, Catholic University of the Sacred Heart, Rome, Italy
J Clin Psychiatry 68:929-34. 2007..The aim of this study was to estimate the effect of atypical and conventional antipsychotics on the risk of hospitalization for femur fracture...
Missed opportunities, missing opportunities and clinical creativityJoseph H Friedman
Med Health R I 88:176. 2005
